{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:02:18Z","timestamp":1794499338088,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Historically, distinct mitochondrial syndromes were recognised clinically by their ocular features. Due to their predilection for metabolically active tissue, mitochondrial diseases frequently involve the eye, resulting in a range of ophthalmic manifestations including progressive external ophthalmoplegia, retinopathy and optic neuropathy, as well as deficiencies of the retrochiasmal visual pathway. With the wider availability of genetic testing in clinical practice, it is now recognised that genotype-phenotype correlations in mitochondrial diseases can be imprecise: many classic syndromes can be associated with multiple genes and genetic variants, and the same genetic variant can have multiple clinical presentations, including subclinical ophthalmic manifestations in individuals who are otherwise asymptomatic. Previously considered rare diseases with no effective treatments, considerable progress has been made in our understanding of mitochondrial diseases with new therapies emerging, in particular, gene therapy for inherited optic neuropathies.<\/jats:p>","DOI":"10.1038\/s41433-023-02523-x","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T13:04:40Z","timestamp":1682427880000},"page":"2416-2425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Mitochondria and the eye\u2014manifestations of mitochondrial diseases and their management"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-0186","authenticated-orcid":false,"given":"Benson S.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Gilhooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3092-7451","authenticated-orcid":false,"given":"Neringa","family":"Jurkute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7847-9320","authenticated-orcid":false,"given":"Patrick","family":"Yu-Wai-Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"2523_CR1","doi-asserted-by":"publisher","first-page":"a021220","DOI":"10.1101\/cshperspect.a021220","volume":"5","author":"DC Wallace","year":"2013","unstructured":"Wallace DC, Chalkia D. Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harb Perspect Biol. 2013;5:a021220.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2523_CR2","first-page":"125","volume":"5","author":"A Von Graefe","year":"1868","unstructured":"Von Graefe A. Verhandlungen arztlicher gesellschaften. Berliner medicinische gesellschaft. Berl Klin Wschr. 1868;5:125\u20137.","journal-title":"Berl Klin Wschr"},{"key":"2523_CR3","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1167\/iovs.14-14466","volume":"55","author":"P Yu-Wai-Man","year":"2014","unstructured":"Yu-Wai-Man P, Clements AL, Nesbitt V, Griffiths PG, Gorman GS, Schaefer AM, et al. A national epidemiological study of chronic progressive external ophthalmoplegia in the United Kingdom - molecular genetic features and neurological burden. Investig Ophthalmol Vis Sci. 2014;55:5109\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2523_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/01676830.2022.2122514","volume":"42","author":"RB Park","year":"2023","unstructured":"Park RB, Akella SS, Aakalu VK. A review of surgical management of progressive myogenic ptosis. Orbit. 2023;42:11\u201324.","journal-title":"Orbit"},{"key":"2523_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/WNO.0000000000000384","volume":"36","author":"RC Bucelli","year":"2016","unstructured":"Bucelli RC, Lee MS, McClelland CM. Chronic progressive external ophthalmoplegia in the absence of ptosis. J Neuroophthalmol. 2016;36:270\u20134.","journal-title":"J Neuroophthalmol"},{"key":"2523_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1136\/bjo.2009.165639","volume":"94","author":"AE Ritchie","year":"2010","unstructured":"Ritchie AE, Griffiths PG, Chinnery PF, Davidson AW. Eye movement recordings to investigate a supranuclear component in chronic progressive external ophthalmoplegia: a cross-sectional study. Br J Ophthalmol. 2010;94:1165\u20138.","journal-title":"Br J Ophthalmol"},{"key":"2523_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0652-7","volume":"16","author":"C McClelland","year":"2016","unstructured":"McClelland C, Manousakis G, Lee MS. Progressive external ophthalmoplegia. Curr Neurol Neurosci Rep. 2016;16:53.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2523_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/archopht.1958.00940080296016","volume":"60","author":"TP Kearns","year":"1958","unstructured":"Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmophegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol. 1958;60:280\u20139.","journal-title":"AMA Arch Ophthalmol"},{"key":"2523_CR9","first-page":"559","volume":"63","author":"TP Kearns","year":"1965","unstructured":"Kearns TP. External ophthalmoplegia, pigmentary degeneration of the retina, and cardiomyopathy: a newly recognized syndrome. Trans Am Ophthalmol Soc. 1965;63:559\u2013625.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2523_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/01.WNL.0000154518.31302.ED","volume":"64","author":"AM Remes","year":"2005","unstructured":"Remes AM, Majamaa-Voltti K, Karppa M, Moilanen JS, Uimonen S, Helander H, et al. Prevalence of large-scale mitochondrial DNA deletions in an adult Finnish population. Neurology. 2005;64:976\u201381.","journal-title":"Neurology"},{"key":"2523_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S0022-3476(79)80286-3","volume":"95","author":"HA Pearson","year":"1979","unstructured":"Pearson HA, Lobel JS, Kocoshis SA, Naiman JL, Windmiller J, Lammi AT, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr. 1979;95:976\u201384.","journal-title":"J Pediatr"},{"key":"2523_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17474086.2018.1426454","volume":"11","author":"P Farruggia","year":"2018","unstructured":"Farruggia P, Di Marco F, Dufour C. Pearson syndrome. Expert Rev Hematol. 2018;11:239\u201346.","journal-title":"Expert Rev Hematol"},{"key":"2523_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.mito.2019.09.002","volume":"49","author":"JN Heighton","year":"2019","unstructured":"Heighton JN, Brady LI, Sadikovic B, Bulman DE, Tarnopolsky MA. Genotypes of chronic progressive external ophthalmoplegia in a large adult-onset cohort. Mitochondrion. 2019;49:227\u201331.","journal-title":"Mitochondrion"},{"key":"2523_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S031716710001115X","volume":"38","author":"G Pfeffer","year":"2011","unstructured":"Pfeffer G, Sirrs S, Wade NK, Mezei MM. Multisystem disorder in late-onset chronic progressive external ophthalmoplegia. Can J Neurol Sci. 2011;38:119\u201323.","journal-title":"Can J Neurol Sci"},{"key":"2523_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/bjo.71.4.290","volume":"71","author":"CM Lane","year":"1987","unstructured":"Lane CM, Collin JR. Treatment of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol. 1987;71:290\u20134.","journal-title":"Br J Ophthalmol"},{"key":"2523_CR16","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1177\/1120672120952344","volume":"31","author":"M Eshaghi","year":"2021","unstructured":"Eshaghi M, Arabi A, Eshaghi S. Surgical management of ptosis in chronic progressive external ophthalmoplegia. Eur J Ophthalmol. 2021;31:2064\u20138.","journal-title":"Eur J Ophthalmol"},{"key":"2523_CR17","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/bjo.2008.144816","volume":"92","author":"J Ahn","year":"2008","unstructured":"Ahn J, Kim NJ, Choung HK, Hwang SW, Sung M, Lee MJ, et al. Frontalis sling operation using silicone rod for the correction of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol. 2008;92:1685\u20138.","journal-title":"Br J Ophthalmol"},{"key":"2523_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0161-6420(97)30250-4","volume":"104","author":"DK Wallace","year":"1997","unstructured":"Wallace DK, Sprunger DT, Helveston EM, Ellis FD. Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Ophthalmology. 1997;104:695\u2013700.","journal-title":"Ophthalmology"},{"key":"2523_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.eye.6701488","volume":"19","author":"C Richardson","year":"2005","unstructured":"Richardson C, Smith T, Schaefer A, Turnbull D, Griffiths P. Ocular motility findings in chronic progressive external ophthalmoplegia. Eye. 2005;19:258\u201363.","journal-title":"Eye"},{"key":"2523_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/09273971003758388","volume":"18","author":"C Tinley","year":"2010","unstructured":"Tinley C, Dawson E, Lee J. The management of strabismus in patients with chronic progressive external ophthalmoplegia. Strabismus. 2010;18:41\u20137.","journal-title":"Strabismus"},{"key":"2523_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0002-9394(14)71041-4","volume":"123","author":"JA Sorkin","year":"1997","unstructured":"Sorkin JA, Shoffner JM, Grossniklaus HE, Drack AV, Lambert SR. Strabismus and mitochondrial defects in chronic progressive external ophthalmoplegia. Am J Ophthalmol. 1997;123:235\u201342.","journal-title":"Am J Ophthalmol"},{"key":"2523_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/ijms23010210","volume":"23","author":"M Zeviani","year":"2021","unstructured":"Zeviani M, Carelli V. Mitochondrial retinopathies. Int J Mol Sci. 2021;23:210.","journal-title":"Int J Mol Sci"},{"key":"2523_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mito.2017.03.006","volume":"36","author":"E Lefevere","year":"2017","unstructured":"Lefevere E, Toft-Kehler AK, Vohra R, Kolko M, Moons L, Van Hove I. Mitochondrial dysfunction underlying outer retinal diseases. Mitochondrion. 2017;36:66\u201376.","journal-title":"Mitochondrion"},{"key":"2523_CR24","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/archopht.1985.01050120059020","volume":"103","author":"MA Mullie","year":"1985","unstructured":"Mullie MA, Harding AE, Petty RK, Ikeda H, Morgan-Hughes JA, Sanders MD. The retinal manifestations of mitochondrial myopathy. A study of 22 cases. Arch Ophthalmol. 1985;103:1825\u201330.","journal-title":"Arch Ophthalmol"},{"key":"2523_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.oret.2021.02.017","volume":"6","author":"J Birtel","year":"2022","unstructured":"Birtel J, von Landenberg C, Gliem M, Gliem C, Reimann J, Kunz WS, et al. Mitochondrial retinopathy. Ophthalmol Retin. 2022;6:65\u201379.","journal-title":"Ophthalmol Retin"},{"key":"2523_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/jnnp-2012-303528","volume":"84","author":"V Nesbitt","year":"2013","unstructured":"Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation-implications for diagnosis and management. J Neurol Neurosurg Psychiatry. 2013;84:936\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2523_CR27","first-page":"428","volume":"46","author":"IJ Holt","year":"1990","unstructured":"Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet. 1990;46:428\u201333.","journal-title":"Am J Hum Genet"},{"key":"2523_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/archopht.118.2.298","volume":"118","author":"JB Kerrison","year":"2000","unstructured":"Kerrison JB, Biousse V, Newman NJ. Retinopathy of NARP syndrome. Arch Ophthalmol. 2000;118:298\u20139.","journal-title":"Arch Ophthalmol"},{"key":"2523_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ana.20555","volume":"58","author":"MT Rantamaki","year":"2005","unstructured":"Rantamaki MT, Soini HK, Finnila SM, Majamaa K, Udd B. Adult-onset ataxia and polyneuropathy caused by mitochondrial 8993T->C mutation. Ann Neurol. 2005;58:337\u201340.","journal-title":"Ann Neurol"},{"key":"2523_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/ana.410340612","volume":"34","author":"FM Santorelli","year":"1993","unstructured":"Santorelli FM, Shanske S, Macaya A, DeVivo DC, DiMauro S. The mutation at nt 8993 of mitochondrial DNA is a common cause of Leigh\u2019s syndrome. Ann Neurol. 1993;34:827\u201334.","journal-title":"Ann Neurol"},{"key":"2523_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/jnnp.14.3.216","volume":"14","author":"D Leigh","year":"1951","unstructured":"Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry. 1951;14:216\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2523_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/archneur.59.2.264","volume":"59","author":"V Carelli","year":"2002","unstructured":"Carelli V, Baracca A, Barogi S, Pallotti F, Valentino ML, Montagna P, et al. Biochemical-clinical correlation in patients with different loads of the mitochondrial DNA T8993G mutation. Arch Neurol. 2002;59:264\u201370.","journal-title":"Arch Neurol"},{"key":"2523_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1203\/00006450-199505000-00014","volume":"37","author":"P Makela-Bengs","year":"1995","unstructured":"Makela-Bengs P, Suomalainen A, Majander A, Rapola J, Kalimo H, Nuutila A, et al. Correlation between the clinical symptoms and the proportion of mitochondrial DNA carrying the 8993 point mutation in the NARP syndrome. Pediatr Res. 1995;37:634\u20139.","journal-title":"Pediatr Res"},{"key":"2523_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/ng0892-368","volume":"1","author":"JM van den Ouweland","year":"1992","unstructured":"van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet. 1992;1:368\u201371.","journal-title":"Nat Genet"},{"key":"2523_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00008","volume":"134","author":"PJ Guillausseau","year":"2001","unstructured":"Guillausseau PJ, Massin P, Dubois-LaForgue D, Timsit J, Virally M, Gin H, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med. 2001;134:721\u20138.","journal-title":"Ann Intern Med"},{"key":"2523_CR36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/S0161-6420(99)90356-1","volume":"106","author":"P Massin","year":"1999","unstructured":"Massin P, Virally-Monod M, Vialettes B, Paques M, Gin H, Porokhov B, et al. Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM Group. Ophthalmology. 1999;106:1821\u20137.","journal-title":"Ophthalmology"},{"key":"2523_CR37","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0161-6420(99)90244-0","volume":"106","author":"PR Smith","year":"1999","unstructured":"Smith PR, Bain SC, Good PA, Hattersley AT, Barnett AH, Gibson JM, et al. Pigmentary retinal dystrophy and the syndrome of maternally inherited diabetes and deafness caused by the mitochondrial DNA 3243 tRNA(Leu) A to G mutation. Ophthalmology. 1999;106:1101\u20138.","journal-title":"Ophthalmology"},{"key":"2523_CR38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/archopht.126.3.320","volume":"126","author":"M Michaelides","year":"2008","unstructured":"Michaelides M, Jenkins SA, Bamiou DE, Sweeney MG, Davis MB, Luxon L, et al. Macular dystrophy associated with the A3243G mitochondrial DNA mutation. Distinct retinal and associated features, disease variability, and characterization of asymptomatic family members. Arch Ophthalmol. 2008;126:320\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2523_CR39","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/bjo.2007.131177","volume":"92","author":"PP Rath","year":"2008","unstructured":"Rath PP, Jenkins S, Michaelides M, Smith A, Sweeney MG, Davis MB, et al. Characterisation of the macular dystrophy in patients with the A3243G mitochondrial DNA point mutation with fundus autofluorescence. Br J Ophthalmol. 2008;92:623\u20139.","journal-title":"Br J Ophthalmol"},{"key":"2523_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/01658107.2019.1653935","volume":"44","author":"CA Ovens","year":"2020","unstructured":"Ovens CA, Ahmad K, Fraser CL. Fundus autofluorescence in maternally inherited diabetes and deafness: the gold standard for monitoring maculopathy? Neuroophthalmology. 2020;44:168\u201373.","journal-title":"Neuroophthalmology"},{"key":"2523_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ajo.2020.01.013","volume":"213","author":"PL Muller","year":"2020","unstructured":"Muller PL, Treis T, Pfau M, Esposti SD, Alsaedi A, Maloca P, et al. Progression of retinopathy secondary to maternally inherited diabetes and deafness\u2014evaluation of predicting parameters. Am J Ophthalmol. 2020;213:134\u201344.","journal-title":"Am J Ophthalmol"},{"key":"2523_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1474-4422(22)00174-0","volume":"22","author":"NJ Newman","year":"2017","unstructured":"Newman NJ, Yu-Wai-Man P, Biousse V, Carelli V. Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management. Lancet Neurol. 2022;22:172\u201388.","journal-title":"Lancet Neurol"},{"key":"2523_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/346066","volume":"72","author":"P Yu-Wai-Man","year":"2003","unstructured":"Yu-Wai-Man P, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003;72:333\u20139.","journal-title":"Am J Hum Genet"},{"key":"2523_CR44","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41433-021-01535-9","volume":"36","author":"P Yu-Wai-Man","year":"2022","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, La Morgia C, Biousse V, Bandello FM, et al. Natural history of patients with Leber hereditary optic neuropathy-results from the REALITY study. Eye. 2022;36:818\u201326.","journal-title":"Eye"},{"key":"2523_CR45","doi-asserted-by":"crossref","unstructured":"Barboni P, La Morgia C, Cascavilla ML, Hong EH, Battista M, Majander A, et al. Childhood-onset leber hereditary optic neuropathy - clinical and prognostic insights. Am J Ophthalmol. 2022.","DOI":"10.1016\/j.ajo.2022.12.014"},{"key":"2523_CR46","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.ajhg.2021.09.015","volume":"108","author":"MIG Lopez Sanchez","year":"2021","unstructured":"Lopez Sanchez MIG, Kearns LS, Staffieri SE, Clarke L, McGuinness MB, Meteoukki W, et al. Establishing risk of vision loss in Leber hereditary optic neuropathy. Am J Hum Genet. 2021;108:2159\u201370.","journal-title":"Am J Hum Genet"},{"key":"2523_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01032-8","volume":"20","author":"AJ Mejia-Vergara","year":"2020","unstructured":"Mejia-Vergara AJ, Seleme N, Sadun AA, Karanjia R. Pathophysiology of conversion to symptomatic leber hereditary optic neuropathy and therapeutic implications: a review. Curr Neurol Neurosci Rep. 2020;20:11.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2523_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13353-020-00550-y","volume":"61","author":"E Jankauskaite","year":"2020","unstructured":"Jankauskaite E, Ambroziak AM, Hajieva P, Oldak M, Tonska K, Korwin M, et al. Testosterone increases apoptotic cell death and decreases mitophagy in Leber\u2019s hereditary optic neuropathy cells. J Appl Genet. 2020;61:195\u2013203.","journal-title":"J Appl Genet"},{"key":"2523_CR49","first-page":"6921","volume":"24","author":"A Pisano","year":"2015","unstructured":"Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, et al. Targeting estrogen receptor beta as preventive therapeutic strategy for Leber\u2019s hereditary optic neuropathy. Hum Mol Genet. 2015;24:6921\u201331.","journal-title":"Hum Mol Genet"},{"key":"2523_CR50","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.ophtha.2013.04.022","volume":"120","author":"P Yu-Wai-Man","year":"2013","unstructured":"Yu-Wai-Man P, Chinnery PF. Dominant optic atrophy: novel OPA1 mutations and revised prevalence estimates. Ophthalmology. 2013;120:1712.e1711.","journal-title":"Ophthalmology"},{"key":"2523_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/79944","volume":"26","author":"C Alexander","year":"2000","unstructured":"Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet. 2000;26:211\u20135.","journal-title":"Nat Genet"},{"key":"2523_CR52","doi-asserted-by":"publisher","first-page":"e0253987","DOI":"10.1371\/journal.pone.0253987","volume":"16","author":"N Weisschuh","year":"2021","unstructured":"Weisschuh N, Schimpf-Linzenbold S, Mazzola P, Kieninger S, Xiao T, Kellner U, et al. Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants. PLoS One. 2021;16:e0253987.","journal-title":"PLoS One"},{"key":"2523_CR53","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.ophtha.2009.12.038","volume":"117","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology. 2010;117:1538\u201346. 1546.e1531","journal-title":"Ophthalmology"},{"key":"2523_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awq007","volume":"133","author":"P Yu-Wai-Man","year":"2010","unstructured":"Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771\u201386.","journal-title":"Brain"},{"key":"2523_CR55","doi-asserted-by":"publisher","first-page":"681326","DOI":"10.3389\/fneur.2021.681326","volume":"12","author":"V Del Dotto","year":"2021","unstructured":"Del Dotto V, Carelli V. Dominant Optic Atrophy (DOA): modeling the kaleidoscopic roles of OPA1 in mitochondrial homeostasis. Front Neurol. 2021;12:681326.","journal-title":"Front Neurol"},{"key":"2523_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/brain\/awm298","volume":"131","author":"P Amati-Bonneau","year":"2008","unstructured":"Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy \u2018plus\u2019 phenotypes. Brain. 2008;131:338\u201351.","journal-title":"Brain"},{"key":"2523_CR57","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/sj.cdd.4402048","volume":"14","author":"A Olichon","year":"2007","unstructured":"Olichon A, Elachouri G, Baricault L, Delettre C, Belenguer P, Lenaers G. OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Differ. 2007;14:682\u201392.","journal-title":"Cell Death Differ"},{"key":"2523_CR58","doi-asserted-by":"crossref","unstructured":"Muench NA, Patel S, Maes ME, Donahue RJ, Ikeda A, Nickells RW. The influence of mitochondrial dynamics and function on retinal ganglion cell susceptibility in optic nerve disease. Cells. 2021;10:1593.","DOI":"10.3390\/cells10071593"},{"key":"2523_CR59","doi-asserted-by":"publisher","first-page":"676187","DOI":"10.3389\/fmolb.2021.676187","volume":"8","author":"T Pass","year":"2021","unstructured":"Pass T, Wiesner RJ, Pla-Martin D. Selective neuron vulnerability in common and rare diseases-mitochondria in the focus. Front Mol Biosci. 2021;8:676187.","journal-title":"Front Mol Biosci"},{"key":"2523_CR60","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s11910-022-01246-y","volume":"22","author":"BS Chen","year":"2022","unstructured":"Chen BS, Yu-Wai-Man P, Newman NJ. Developments in the treatment of leber hereditary optic neuropathy. Curr Neurol Neurosci Rep. 2022;22:881\u201392.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2523_CR61","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/WNO.0000000000001023","volume":"40","author":"CB Catarino","year":"2020","unstructured":"Catarino CB, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, et al. Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. J Neuroophthalmol. 2020;40:558\u201365.","journal-title":"J Neuroophthalmol"},{"key":"2523_CR62","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/WNO.0000000000000570","volume":"37","author":"V Carelli","year":"2017","unstructured":"Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagreze WA, et al. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. J Neuroophthalmol. 2017;37:371\u201381.","journal-title":"J Neuroophthalmol"},{"key":"2523_CR63","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/acn3.51026","volume":"7","author":"M Romagnoli","year":"2020","unstructured":"Romagnoli M, La Morgia C, Carbonelli M, Di Vito L, Amore G, Zenesini C, et al. Idebenone increases chance of stabilization\/recovery of visual acuity in OPA1-dominant optic atrophy. Ann Clin Transl Neurol. 2020;7:590\u20134.","journal-title":"Ann Clin Transl Neurol"},{"key":"2523_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep21587","volume":"6","author":"X Wan","year":"2016","unstructured":"Wan X, Pei H, Zhao MJ, Yang S, Hu WK, He H, et al. Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy. Sci Rep. 2016;6:21587.","journal-title":"Sci Rep"},{"key":"2523_CR65","doi-asserted-by":"publisher","first-page":"eaaz7423","DOI":"10.1126\/scitranslmed.aaz7423","volume":"12","author":"P Yu-Wai-Man","year":"2020","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020;12:eaaz7423.","journal-title":"Sci Transl Med"},{"key":"2523_CR66","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","volume":"128","author":"NJ Newman","year":"2021","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2021;128:649\u201360.","journal-title":"Ophthalmology"},{"key":"2523_CR67","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/brain\/awac421","volume":"146","author":"NJ Newman","year":"2022","unstructured":"Newman NJ, Yu-Wai-Man P, Subramanian PS, Moster ML, Wang AG, Donahue SP, et al. Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy. Brain. 2022;146:1328\u201341.","journal-title":"Brain"},{"key":"2523_CR68","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41434-022-00333-6","volume":"29","author":"Y Liu","year":"2022","unstructured":"Liu Y, Eastwood JD, Alba DE, Velmurugan S, Sun N, Porciatti V, et al. Gene therapy restores mitochondrial function and protects retinal ganglion cells in optic neuropathy induced by a mito-targeted mutant ND1 gene. Gene Ther. 2022;29:368\u201378.","journal-title":"Gene Ther"},{"key":"2523_CR69","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/bs.mcb.2019.12.004","volume":"155","author":"SR Bacman","year":"2020","unstructured":"Bacman SR, Gammage PA, Minczuk M, Moraes CT. Manipulation of mitochondrial genes and mtDNA heteroplasmy. Methods Cell Biol. 2020;155:441\u201387.","journal-title":"Methods Cell Biol"},{"key":"2523_CR70","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/s41587-022-01256-8","volume":"40","author":"BY Mok","year":"2022","unstructured":"Mok BY, Kotrys AV, Raguram A, Huang TP, Mootha VK, Liu DR. CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA. Nat Biotechnol. 2022;40:1378\u201387.","journal-title":"Nat Biotechnol"},{"key":"2523_CR71","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nature11800","volume":"493","author":"D Paull","year":"2013","unstructured":"Paull D, Emmanuele V, Weiss KA, Treff N, Stewart L, Hua H, et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature. 2013;493:632\u20137.","journal-title":"Nature"},{"key":"2523_CR72","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMc1500960","volume":"372","author":"GS Gorman","year":"2015","unstructured":"Gorman GS, Grady JP, Turnbull DM. Mitochondrial donation-how many women could benefit? N. Engl J Med. 2015;372:885\u20137.","journal-title":"N. Engl J Med"},{"key":"2523_CR73","unstructured":"Stoke Therapeutics. Stoke therapeutics reports third quarter financial results and provides business updates. https:\/\/investor.stoketherapeutics.com\/news-releases\/news-release-details\/stoke-therapeutics-reports-third-quarter-financial-results-and-0. Accessed 18 Oct 2022."},{"key":"2523_CR74","unstructured":"PYC Therapeutics. PYC Therapeutics Set To Announce Efficacy Results For Second Investigational Drug Program. https:\/\/pyctx.com\/wp-content\/uploads\/2021\/05\/PYC-Therapeutics-Set-To-Announce-Efficacy-Results-For-Second-Investigational-Drug-Program.pdf Accessed 18 Oct 2022."},{"key":"2523_CR75","first-page":"2373","volume":"51","author":"Y Goto","year":"1993","unstructured":"Goto Y. MELAS (mitochondrial myopathy, encephalopathy lactic acidosis, and stroke-like episodes): clinical features and mitochondrial DNA mutations. Nihon Rinsho. 1993;51:2373\u20138.","journal-title":"Nihon Rinsho"},{"key":"2523_CR76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0960-8966(92)90045-8","volume":"2","author":"M Hirano","year":"1992","unstructured":"Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 1992;2:125\u201335.","journal-title":"Neuromuscul Disord"},{"key":"2523_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.mito.2020.11.003","volume":"56","author":"A Shinkai","year":"2021","unstructured":"Shinkai A, Shinmei Y, Hirooka K, Tagawa Y, Nakamura K, Chin S, et al. Optical coherence tomography as a possible tool to monitor and predict disease progression in mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. Mitochondrion. 2021;56:47\u201351.","journal-title":"Mitochondrion"},{"key":"2523_CR78","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00417-002-0555-y","volume":"240","author":"T Latvala","year":"2002","unstructured":"Latvala T, Mustonen E, Uusitalo R, Majamaa K. Pigmentary retinopathy in patients with the MELAS mutation 3243A->G in mitochondrial DNA. Graefes Arch Clin Exp Ophthalmol. 2002;240:795\u2013801.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2523_CR79","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1042\/EBC20170114","volume":"62","author":"M Hirano","year":"2018","unstructured":"Hirano M, Emmanuele V, Quinzii CM. Emerging therapies for mitochondrial diseases. Essays Biochem. 2018;62:467\u201381.","journal-title":"Essays Biochem"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02523-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02523-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02523-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T11:09:02Z","timestamp":1690974542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02523-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2523"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02523-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PYWM is a consultant for GenSight Biologics, Santhera\/Chiesi, Stoke Therapeutics and Transine Therapeutics. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}